Travere Therapeutics (TVTX) Liabilities from Discontinued Operations (2022)
Travere Therapeutics (TVTX) posted Liabilities from Discontinued Operations of 64200000.0 for Q4 2022.
Travere Therapeutics (TVTX) Liabilities from Discontinued Operations (2022) Analysis & Trends
Travere Therapeutics' Liabilities from Discontinued Operations history runs 1 years deep, the most recent figure standing at 64200000.0 for Q4 2022.
- Quarterly Liabilities from Discontinued Operations changed N/A year-over-year to 64200000.0 in Q4 2022, while the trailing twelve-month figure through Dec 2022 was 64200000.0 (changed N/A YoY) and the FY2022 annual result came in at 64200000.0, changed N/A from the prior year.
- Liabilities from Discontinued Operations was 64200000.0 for Q4 2022 at Travere Therapeutics.
- Across five years, Liabilities from Discontinued Operations topped out at 64200000.0 in Q4 2022 and bottomed at 64200000.0 in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Travere Therapeutics | 5.21 Bn | 5.21 Bn | 125.25 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 64.20 Mn |
| Dec 31, 2022 | 64.20 Mn |